Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience

Background: Response to neoadjuvant chemotherapy (NACT) has been proven to be an established prognostic factor after open radical cystectomy (ORC). We evaluated the impact of NACT on survival outcomes of a single-institution robotic radical cystectomy (RARC) series. Methods: From January 2012 to Jun...

Full description

Bibliographic Details
Main Authors: Umberto Anceschi, Aldo Brassetti, Gabriele Tuderti, Maria Consiglia Ferriero, Manuela Costantini, Alfredo Maria Bove, Fabio Calabrò, Paolo Carlini, Sabrina Vari, Riccardo Mastroianni, Michele Gallucci, Giuseppe Simone
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/9/9/2736
id doaj-dbd20f76a35b4126afab7bb6295832a8
record_format Article
spelling doaj-dbd20f76a35b4126afab7bb6295832a82020-11-25T03:40:07ZengMDPI AGJournal of Clinical Medicine2077-03832020-08-0192736273610.3390/jcm9092736Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center ExperienceUmberto Anceschi0Aldo Brassetti1Gabriele Tuderti2Maria Consiglia Ferriero3Manuela Costantini4Alfredo Maria Bove5Fabio Calabrò6Paolo Carlini7Sabrina Vari8Riccardo Mastroianni9Michele Gallucci10Giuseppe Simone11Department of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Oncology, San Camillo-Forlanini Hospital, Rome, Circonvallazione Gianicolense 87, 00152 Rome, ItalyDepartment of Oncology, Regina Elena National Cancer Institute, Rome, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Oncology, Regina Elena National Cancer Institute, Rome, Via Elio Chianesi 53, 00144 Rome, ItalyDepartment of Urology, University of Rome, La Sapienza, Rome, Viale del Policlinico 155, 00161 Rome, ItalyDepartment of Urology, University of Rome, La Sapienza, Rome, Viale del Policlinico 155, 00161 Rome, ItalyDepartment of Urology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, ItalyBackground: Response to neoadjuvant chemotherapy (NACT) has been proven to be an established prognostic factor after open radical cystectomy (ORC). We evaluated the impact of NACT on survival outcomes of a single-institution robotic radical cystectomy (RARC) series. Methods: From January 2012 to June 2020, 79 patients were identified. Baseline, demographic, perioperative, and pathologic data were described. Kaplan–Meier with the log-rank test was used to compare overall survival (OS) differences between complete, partial, and no-NACT responders, respectively. Univariable and multivariable regression analyses were performed to identify predictors of OS. Results: Complete, partial, and absent response to NACT were recorded in 43 (54.4%), 21 (19%), and 15 (26.6%) patients, respectively. A complete response to NACT displayed a trend toward significant higher OS (<i>p </i>=<i> </i>0.03). In univariable analysis, significant predictors of lower OS were hypertension (HR 3.37; CI 95% 1.31–8.62; <i>p </i>=<i> </i>0.01); advanced nodal involvement (HR 2.41; CI 95% 0.53–10.9; <i>p </i><<i> </i>0.001); and incomplete response to NACT (HR 0.41; CI 95% 0.18–0.95; <i>p </i>=<i> </i>0.039). In multivariable analysis, the only independent predictor of worse OS was advanced pathologic N stages (HR 10.1; CI: 95% CI 2.3–44.3; <i>p </i>=<i> </i>0.002). Conclusions: Complete response to NACT is associated with increased OS probability, but significant nodal residual disease remains the only independent predictor of OS after RARC.https://www.mdpi.com/2077-0383/9/9/2736neoadjuvant chemotherapyclinical responserobotic radical cystectomymuscle-invasive bladder cancerlymphadenectomyoverall survival
collection DOAJ
language English
format Article
sources DOAJ
author Umberto Anceschi
Aldo Brassetti
Gabriele Tuderti
Maria Consiglia Ferriero
Manuela Costantini
Alfredo Maria Bove
Fabio Calabrò
Paolo Carlini
Sabrina Vari
Riccardo Mastroianni
Michele Gallucci
Giuseppe Simone
spellingShingle Umberto Anceschi
Aldo Brassetti
Gabriele Tuderti
Maria Consiglia Ferriero
Manuela Costantini
Alfredo Maria Bove
Fabio Calabrò
Paolo Carlini
Sabrina Vari
Riccardo Mastroianni
Michele Gallucci
Giuseppe Simone
Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience
Journal of Clinical Medicine
neoadjuvant chemotherapy
clinical response
robotic radical cystectomy
muscle-invasive bladder cancer
lymphadenectomy
overall survival
author_facet Umberto Anceschi
Aldo Brassetti
Gabriele Tuderti
Maria Consiglia Ferriero
Manuela Costantini
Alfredo Maria Bove
Fabio Calabrò
Paolo Carlini
Sabrina Vari
Riccardo Mastroianni
Michele Gallucci
Giuseppe Simone
author_sort Umberto Anceschi
title Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience
title_short Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience
title_full Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience
title_fullStr Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience
title_full_unstemmed Impact of Clinical Response to Neoadjuvant Chemotherapy in the Era of Robot Assisted Radical Cystectomy: Results of a Single-Center Experience
title_sort impact of clinical response to neoadjuvant chemotherapy in the era of robot assisted radical cystectomy: results of a single-center experience
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2020-08-01
description Background: Response to neoadjuvant chemotherapy (NACT) has been proven to be an established prognostic factor after open radical cystectomy (ORC). We evaluated the impact of NACT on survival outcomes of a single-institution robotic radical cystectomy (RARC) series. Methods: From January 2012 to June 2020, 79 patients were identified. Baseline, demographic, perioperative, and pathologic data were described. Kaplan–Meier with the log-rank test was used to compare overall survival (OS) differences between complete, partial, and no-NACT responders, respectively. Univariable and multivariable regression analyses were performed to identify predictors of OS. Results: Complete, partial, and absent response to NACT were recorded in 43 (54.4%), 21 (19%), and 15 (26.6%) patients, respectively. A complete response to NACT displayed a trend toward significant higher OS (<i>p </i>=<i> </i>0.03). In univariable analysis, significant predictors of lower OS were hypertension (HR 3.37; CI 95% 1.31–8.62; <i>p </i>=<i> </i>0.01); advanced nodal involvement (HR 2.41; CI 95% 0.53–10.9; <i>p </i><<i> </i>0.001); and incomplete response to NACT (HR 0.41; CI 95% 0.18–0.95; <i>p </i>=<i> </i>0.039). In multivariable analysis, the only independent predictor of worse OS was advanced pathologic N stages (HR 10.1; CI: 95% CI 2.3–44.3; <i>p </i>=<i> </i>0.002). Conclusions: Complete response to NACT is associated with increased OS probability, but significant nodal residual disease remains the only independent predictor of OS after RARC.
topic neoadjuvant chemotherapy
clinical response
robotic radical cystectomy
muscle-invasive bladder cancer
lymphadenectomy
overall survival
url https://www.mdpi.com/2077-0383/9/9/2736
work_keys_str_mv AT umbertoanceschi impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT aldobrassetti impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT gabrieletuderti impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT mariaconsigliaferriero impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT manuelacostantini impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT alfredomariabove impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT fabiocalabro impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT paolocarlini impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT sabrinavari impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT riccardomastroianni impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT michelegallucci impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
AT giuseppesimone impactofclinicalresponsetoneoadjuvantchemotherapyintheeraofrobotassistedradicalcystectomyresultsofasinglecenterexperience
_version_ 1724536239734915072